Re: No mention of efficacy again...
in response to
by
posted on
Mar 29, 2019 04:07PM
Buckeyes, where do you stand?
Do you agree with Bear, that there is a reasonable argument for a $5-$7 billion valuation at this point in time if this is what you are stating?
"$5-$7 billion would be a reasonable offer right now, pre-top-line, with the buying big pharma assuming the risk of BETonMACE failure."
Koo